Recombinant Modified Vaccinia Virus Ankara (MVA) Expressing Wild-Type Human p53 Induces Specific Antitumor CTL Expansion

The p53 gene product is an attractive target for tumor immunotherapy. The present study aims to understand the potential of MVAp53 vaccine to induce expansion of p53-specific cytotoxic T lymphocyte ex vivo in cancer patients. The result indicated that 14 of 23 cancer patients demonstrated p53-specif...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Guang-Yun, Srivastava, Tumul, Ishizaki, Hidenobu, Lacey, Simon F., Diamond, Don J., Ellenhorn, Joshua D. I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2011
Materias:
Cellular and Molecular Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3260009/
https://www.ncbi.nlm.nih.gov/pubmed/21843052
http://dx.doi.org/10.3109/07357907.2011.606248
_version_ 1782221425112776704
author Song, Guang-Yun
Srivastava, Tumul
Ishizaki, Hidenobu
Lacey, Simon F.
Diamond, Don J.
Ellenhorn, Joshua D. I.
author_facet Song, Guang-Yun
Srivastava, Tumul
Ishizaki, Hidenobu
Lacey, Simon F.
Diamond, Don J.
Ellenhorn, Joshua D. I.
author_sort Song, Guang-Yun
collection PubMed
description The p53 gene product is an attractive target for tumor immunotherapy. The present study aims to understand the potential of MVAp53 vaccine to induce expansion of p53-specific cytotoxic T lymphocyte ex vivo in cancer patients. The result indicated that 14 of 23 cancer patients demonstrated p53-specific IFN-γ production, degranulation, cell proliferation, and lysis of p53 overexpressed human tumor cell lines. These experiments show that MVAp53 stimulation has the potential to induce the expansion of p53-specific cytotoxic T lymphocyte from the memory T cell repertoire. The data suggest that MVAp53 vaccine is an ideal candidate for cancer immunotherapy.
format Online
Article
Text
id pubmed-3260009
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-32600092012-10-01 Recombinant Modified Vaccinia Virus Ankara (MVA) Expressing Wild-Type Human p53 Induces Specific Antitumor CTL Expansion Song, Guang-Yun Srivastava, Tumul Ishizaki, Hidenobu Lacey, Simon F. Diamond, Don J. Ellenhorn, Joshua D. I. Cancer Invest Cellular and Molecular Biology The p53 gene product is an attractive target for tumor immunotherapy. The present study aims to understand the potential of MVAp53 vaccine to induce expansion of p53-specific cytotoxic T lymphocyte ex vivo in cancer patients. The result indicated that 14 of 23 cancer patients demonstrated p53-specific IFN-γ production, degranulation, cell proliferation, and lysis of p53 overexpressed human tumor cell lines. These experiments show that MVAp53 stimulation has the potential to induce the expansion of p53-specific cytotoxic T lymphocyte from the memory T cell repertoire. The data suggest that MVAp53 vaccine is an ideal candidate for cancer immunotherapy. Taylor & Francis 2011-09-14 /pmc/articles/PMC3260009/ /pubmed/21843052 http://dx.doi.org/10.3109/07357907.2011.606248 Text en © 2011 Informa Healthcare USA, Inc. This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the monkeypox public health emergency or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
spellingShingle Cellular and Molecular Biology
Song, Guang-Yun
Srivastava, Tumul
Ishizaki, Hidenobu
Lacey, Simon F.
Diamond, Don J.
Ellenhorn, Joshua D. I.
Recombinant Modified Vaccinia Virus Ankara (MVA) Expressing Wild-Type Human p53 Induces Specific Antitumor CTL Expansion
title Recombinant Modified Vaccinia Virus Ankara (MVA) Expressing Wild-Type Human p53 Induces Specific Antitumor CTL Expansion
title_full Recombinant Modified Vaccinia Virus Ankara (MVA) Expressing Wild-Type Human p53 Induces Specific Antitumor CTL Expansion
title_fullStr Recombinant Modified Vaccinia Virus Ankara (MVA) Expressing Wild-Type Human p53 Induces Specific Antitumor CTL Expansion
title_full_unstemmed Recombinant Modified Vaccinia Virus Ankara (MVA) Expressing Wild-Type Human p53 Induces Specific Antitumor CTL Expansion
title_short Recombinant Modified Vaccinia Virus Ankara (MVA) Expressing Wild-Type Human p53 Induces Specific Antitumor CTL Expansion
title_sort recombinant modified vaccinia virus ankara (mva) expressing wild-type human p53 induces specific antitumor ctl expansion
topic Cellular and Molecular Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3260009/
https://www.ncbi.nlm.nih.gov/pubmed/21843052
http://dx.doi.org/10.3109/07357907.2011.606248
work_keys_str_mv AT songguangyun recombinantmodifiedvacciniavirusankaramvaexpressingwildtypehumanp53inducesspecificantitumorctlexpansion
AT srivastavatumul recombinantmodifiedvacciniavirusankaramvaexpressingwildtypehumanp53inducesspecificantitumorctlexpansion
AT ishizakihidenobu recombinantmodifiedvacciniavirusankaramvaexpressingwildtypehumanp53inducesspecificantitumorctlexpansion
AT laceysimonf recombinantmodifiedvacciniavirusankaramvaexpressingwildtypehumanp53inducesspecificantitumorctlexpansion
AT diamonddonj recombinantmodifiedvacciniavirusankaramvaexpressingwildtypehumanp53inducesspecificantitumorctlexpansion
AT ellenhornjoshuadi recombinantmodifiedvacciniavirusankaramvaexpressingwildtypehumanp53inducesspecificantitumorctlexpansion

Ejemplares similares